About IRISS

IRISS received 501 c-6 designation from Internal Revenue Service (IRS) on March 7, 2012. The 501 c-6 designation recognizes IRISS Forum as a pharmaceutical industry trade organization, which provides a mechanism for IRISS to collaborate with other trade organizations within the pharmaceutical industry (ie Pharma, DIA, RAPS, HL7) as well as global Health Authorities. IRISS represents a neutral forum for industry, vendors, health authorities, consultants, etc. to share information and work towards a standard method of implementing electronic submission specifications and improving interoperability of e-publishing tools, viewing tools, and systems.

IRISS Forum operates through a directorship structure, governed by an executive committee and board of directors.

IRISS Operating Policy dated 08/18/2015

Board of Directors:

Donna Whiting (Chair)
Jim Hanly
John Kiser
Rick Riegel
Karen Towns
Hans van Bruggen

Executive Committee:

President / CEO: Jim Nichols
Vice President: Joel Finkle
Treasurer: Gina Ross

Steering Committee:

Chair: Don Palmer (Acuta)
AdPromo Topic Group: Doug Kent (Janssen – J&J Pharma)
CMC Topic Group: Marc Hichens (J&J)
GSO Topic Group: Tracy Naughton (AstraZeneca)
IDMP (XEVMPD) Topic Group: Andrew Marr (Marr Consultancy)
ETICS Special Project: Harv Martens (Independent)
Website Liaison: Lenore Palma (Pharmaceutical eConsulting)
Communications Team: Joel Finkle (CSC Life Sciences)

Page last updated: 27JUL2017